T he ability to choose which proteins are present on a cell's surface can be an important tool for modulating cell behavior. Methods have been designed to artificially add proteins, such as recombinant proteins 1 , glycosylphosphatidyl-inositol-anchored proteins [2] [3] [4] , NHS-functionalized poly(ethylene glycol) oleyl derivatives 5 , and palmitated protein A complexes 6 , to cell membranes. However, recombinant strategies are time-consuming, and the use of lipid-functionalized proteins cannot be modulated. In addition to proteins, several groups have linked cDNA to the surface of cells via lipid attachment 7 or used broad chemical modification of the cell surface 8 in order to attach cells. Building on these attempts, we sought to use aptamers as artificial receptors to capture proteins onto cell surfaces in a rapid, reversible, and dose-controllable manner. Aptamers are short DNA or RNA sequences that bind to specific targets, including proteins. Previously, our group synthesized a diacyllipid phosphoramidite 9 nucleoside building block that has two long-saturated fatty acid chains held together with a 1,3-diamino-2-propanol connector (Figure 1 ). Micelles added to cells actively disassemble and intercalate into or attach onto the cell membrane by hydrophobic interactions 10, 11 . This diacyllipid phosphoramidite can easily be attached to the 59 end of any synthesized oligonucleotide. Thus, in theory, any aptamer can be functionalized with the lipid, which anchors the aptamer in the membrane, where it will protrude from the cell, ready to bind its target. Aptamer-micelles have previously been used to deliver dye-loaded micelles specifically to leukemia cells expressing the aptamer's target protein 11 .
Results
In our first test to capture proteins onto the cell surface, cells were modified with streptavidin (SA) artificial receptors (ARs), enabling them to capture fluorescently labeled SA in a dose-controllable manner. SA is a tetravalent protein that binds the small molecule biotin with a very high affinity K d < 10 214 M, making it a useful tool in cell biology. SA-ARs were made by attaching the lipid tail to a 29-nucleotide (nt) aptamer that binds SA (40 nM K d ) 12 . To confirm that SA-ARs retained their binding ability to SA, FITC-labelled SA-aptamers were competitively removed from SA-coated magnetic beads by SA-AR ( Figure S1 in Supporting Information). All cell lines tested were able to capture Alexa-488-labeled SA (SA-488) on their cell membranes after insertion of SAARs (Figure 2A) . On CEM cells (T-cell leukemia), aptamer insertion is detectable after 5 min and reaches saturation after 1 h ( Figure S2 in Supporting Information).
Incubation of CEM cells with different concentrations of SA-AR resulted in the dose-dependent capture of SA on the cell surface ( Figure 2B ). Specifically, incubation with as little as 31 nM of SA-AR, which is below the K d for the SA aptamer, was sufficient for detection of SA-488 on the cell surface by flow cytometry. Increasing the SA-AR concentration increased the fluorescence signal from SA-488 in a concentration-dependent manner until it reached a plateau at around 5 mM ( Figure 2B ).
SA-ARs persisted on the cell membrane for an extended time, but the amount of aptamer slowly decreased over the 2 days after incubation ( Figure 2C ). After 2 days, fluorescence became undetectable, indicating that SA-AR modification is temporary, and that cells returned to normal after being cultured for 2 days. In fact, SA-AR insertion had no effect on cell proliferation as measured by the standard assay using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Figure 3 ). These results indicate that SA-AR treatment does not negatively affect cell growth, an important criterion for future applications.
Because this SA aptamer does not bind at 37uC, the SA-488 signal on CEM cells dropped to background levels when the temperature was increased from 4uC to 37uC (data not shown). This result demonstrates that the binding of SA-AR to its target SA-488 can be modulated by altering environmental conditions such as temperature. Further, we confirmed that the biotin binding sites on SA were still available for binding ( Figure 4A,B) .
To demonstrate that we could isolate SA-AR-modified cells, we captured SA-AR-functionalized cells with SA-coated DynaBeads ( Figure 4C ). In this experiment, CEM cells were modified with either the control, PDGF-AR, or the target, SA-AR, artificial receptors. When they were mixed with streptravidin-coated magnetic beads in a buffer, the cells were enriched on the beads. After lysing the cells and probing them via Western blot for b-actin, only the 2 positive controls (the sgc8-biotin-bound cells in Lane 3 and the pure cell lysate in Lane 7) and the SA-AR-modified cells (Lane 5) were able to enrich the cells in buffer, indicating the presence of b-actin. The untreated cells (Lane 1), the TD05-biotin (Lane 2), which does not bind CEM, and the PDGF-AR (Lane 4), which does not bind streptavidin, showed no evidence of b-actin. This assay shows that SA-AR can be used to modify cells and then recapture them with SA-coated beads.
In addition to SA-AR, we also prepared a thrombin aptamerreceptor (T27-AR) that captures thrombin, allowing modified cells to cause clotting. Thrombin is an enzyme important in the clotting of blood. When activated, it cleaves its substrate, soluble fibrinogen, into insoluble fibrin. Thrombin has two very well studied aptamers: a 15 nt aptamer (T-15), which binds the fibrinogen cleavage site on thrombin with relatively low affinity (K d 5 450 nM), and a 27 nt aptamer (T-27), important for heparin binding, which has a lower Kd and higher binding affinity (K d 5 0.7 nM). By attaching a lipid tail to T-27, we made a high affinity thrombin-aptamer artificial receptor (T27-AR). The T27-AR binds thrombin through the heparin binding site, leaving the fibrinogen cleavage active site free for binding to fibrinogen or the low affinity T-15 aptamer. We confirmed thrombin bound to the T27-AR modified cell surface by staining the cells with SA-488 tagged T-15 aptamer and measuring their signal by flow ( Figure S3 in Supporting Information).
T-15 binds the fibrinogen cleavage site on thrombin and inhibits the ability to cleave fibrinogen 13, 14 . As the T-15 binding site was clearly exposed on cells modified with thrombin, we asked whether these cells could induce clotting if fibrinogen was added to them. In this assay, we captured thrombin on the surface of CEM cells using the T27-AR, followed by addition of fibrinogen. Cells modified with www.nature.com/scientificreports thrombin clotted fibrinogen within 15 sec ( Figure 5, Tube 3) . The clots had a gel-like consistency visualized by trypan blue. As expected, addition of T-15 to the mixture competed with fibrinogen for access to thrombin's active site, and no clotting was seen (Tube 4). By contrast, when a scrambled T-15 (scrT-15) was added, clotting was recovered (Tube 5). Likewise, use of a control protein, BSA (Tube 6) or a control aptamer-receptor, PDGF-AR (Tube 7), did not cause clotting.
Next, we modified CEM cells with tenascin-C (TNC) aptamer 15 AR to simulate the phenomenon of stem cell homing after an autologous bone marrow transplant. Stem cells rely on their local environment or ''niche'' to survive and differentiate 16 . Outside this niche, hematopoietic stem cells (HSC) cannot function, and do not produce the different lineages necessary to re-establish the blood and immune system. During bone marrow transplants, bone marrow stem cells are injected into a patient's bloodstream where they follow chemoattractive signals to find their stem cell niche. This homing process is not perfect, however, and many cells do not arrive at their proper locations, causing transplant failure. Increasing the homing ability of HSC would relieve this problem.
Tenascin-C is found in the matrix of the stem cell niche and plays a key role in homing hematopoietic cells to their niche 17 . We hypothesized modifying stem cells with TNC-AR would allow the cells to better find and remain in their niche after bone marrow transplants. As a proof of concept, we modified a T-cell leukemia cell-line, CEM, with TNC-AR. Monolayers of MDA-MB-231, a human breast adenocarcinoma cell line high levels of surface tenascin-C, provided our model stem cell niche. To this model niche we added TNC-ARmodified T-cell leukemia CEM cells ( Figure S4 in Supporting Information) 18 and calculated binding. 
Discussion
Artificial aptamer-lipid receptors offer a simple, biomimetic, nontoxic, reversible, and dose-controllable strategy for modifying cell membranes with any protein for which there is a known aptamer. This new strategy is rapid, one-step, reversible, and it does not alter the captured protein, making it an improvement over current methods. In this work we show the ease and flexibility of this approach by modifying cell surfaces for three separate purposes: (1) to label or capture cells with streptavidin; (2) to attach thrombin onto T-cells giving the cells a de novo ability to cleave fibrinogen and cause clotting; and (3) to facilitate binding between two cell types, one modified with TNC-AR and one expressing high levels of TNC, which may be helpful for increasing stem-cell homing after autologous bone marrow transplants.
The cell membrane is the main site for cellular interactions with its environment. By placing temporary receptors on the surface of cells, we have constructed self-assemblies combining several proteins, cell types, or aptamers on the membrane. These complexes imbue the modified cells with new abilities that can be tailored to specific therapeutic or diagnostic needs just by altering the choice of aptamer. With the rise of stem-cell based and other whole-cell based therapies we envision this technology being used to encourage engraftment and make these cellular delivery systems more robust. Methods Materials. Unless otherwise noted, all chemicals and buffers came from SigmaAldrich and were not further purified. All DNA bases, except for the lipidphosphoramidite, which was synthesized in house, were purchased from Glen Research. Oligonucleotides were synthesized in house on an automated ABI 3400 DNA synthesizer from Applied Biosystems. HPLC of the DNA sequences was performed with a Varian Prostar Instrument. UV/Vis measurements for purity and concentration determination were carried out on a Varian Cary 100 spectrophotometer.
DNA synthesis. All DNA sequences were synthesized with an ABI 3400 synthesizer on a 1.0 micromolar scale. Biotinylated CPG lipid phosphoramidite was dissolved in 0.4 mL dichloromethane for coupling. For the lipid-DNA after synthesis, the DNA was cut from the CPG beads and deprotected in ammonium hydroxide at 55uC for 14 h. Next, the DNA was dissolved in 100 mM triethylamine-acetic acid buffer (TEAA, pH7.5) and purified by reverse-phase HPLC using a C4 column with an acetonitrile gradient (0-30 min, 10-100%) as an eluent. For other DNA sequences with no biotin or dye modifications, the sequences were deprotected for 20 min in AMA (151 ammonia hydroxide: 40% methylamine) and purified using Gel-Pak Purification Columns (Glenn Research) followed by desalting on a Nap-5 column (GE Healthcare). The sequences used can be found in Table 1 .
Cell culture. CCRF-CEM cells (T-cell, human acute lymphoblastic leukemia), Ramos (B-cell, human Burkitt's lymphoma), HeLa (human cervical adenocarcinoma), and A549 (human lung adenocarcinoma) were obtained from ATCC (American Type Culture Association). Ludlu-1 cells were obtained from the European Collection of Cell Cultures (ECACC). CEM, Ludlu-1, and Ramos cells were grown in RPMI-1640 media (GIBCO). HeLa cells were grown in Dulbecco's modified Eagle's medium (DMEM, GIBCO). MCF7 cells were grown in Minimal Essential Media (MEM, GIBCO), and A549 cells were grown in F-12k media (GIBCO). All media were supplemented with 10% fetal bovine serum (Invitrogen), and cells were incubated at 37uC in 5% CO 2 .
Flow cytometry. Five-hundred thousand cells were washed with 2 mL washing buffer (WB; 1 3 PBS, 5 mM MgCl 2 , 4.5 g/L glucose) and spun down at 1200 g for 3 min. TT TTT TTA TTG ACC GCT GTG TGA CGC AAC ACT CAA T-39  T27-AR  59 Lipid TT TTT TTG TCC GTG GTA GGG CAG GTT GGG GTG AC-39  PDGF-AR  59 Lipid TT TTT TTC AGG CTA CGG CAC GTA GAG CAT CAC CAT GAT CCT G-39  TNC-AR  59 Lipid TT TTT TTC CCA GAG GGA AGA CTT TAG GTT CGG TTC ACG TCC-39  T-15 FITC  59-GGT TGG TGT GGT TGG FITC-39  T-15 CEM cells were incubated with different concentrations of SA-ARs, ranging from 31 nM to 5 mM, for 2 h at 37uC and washed 3 3. This was followed by addition of 15400 streptavidin-488 (SA-488) (Invitrogen) or streptavidin-phycoerythrin (SA-PE) (Invitrogen) and 30 min incubation at 4uC in WB. Cells were then washed once in WB and analyzed by flow cytometry on a FACScan (Becton Dickinson) using FL-1 for SA-488 and FL-2 for SA-PE. Data were analyzed using either Win-MDI or FCS Express 2.0. All data shown are ungated. To study aptamer-receptor permanence on the cell surface, CEM cells were incubated with 2 mM of SA-AR for 2 h at 37uC, followed by washes and incubation at various times from 0 to 30 h before adding 15400 SA-488, washing, and performing flow analysis.
Microscopy. Cells were plated at low confluence on Lab-Tek four-chambered slides and allowed to grow for 24 h before washing with WB and incubating with 2 mM of SA-ARs for 2 h at 37uC. Afterwards, the cells were washed again 3 3 and incubated with 15400 SA-488 for 30 min at 4uC. After washing, cells were imaged at 40 3 magnification using incubation and imaged by bright field and fluorescence (488 ex) microscopy using a Leica DM6000B microscope.
MTS assay. MTS works on the principle of a cell's ability to reduce the tetrazolium reagent (Owen's Reagent) via NADH or NADPH when it is alive. The reduced product absorbs at 490 nm and can be read at that wavelength; the higher the absorbance, the more viable are the cells. CEM cells (250 K) were washed and placed into sterile flow tubes with 1 mL of RPMI media. For each time point, each tube was treated in the same manner. Two mL of PBS was added, and cells were washed by spinning at 1300RPM for three minutes. The cell medium was removed by pouring out the supernatant, and cells were incubated with 50 mL 500 nM streptavidin-Lipid #3 for 1-2 h at 37uC. Two mL PBS was used to wash the cells. Then the cells in each tube were resuspended in 1 mL RPMI. Finally cells were washed, resuspeded in 100 uL RPMI, and split into three 96-well plates to which 20 mL MTS reagent CellTiter 96 Aqueous Non-Radioactive Cell Proliferation (Promega) was added. Cells were measured at 490 nm after 4 h. The wells were all bright purple.
Cell capture with streptavidin DynaBeads. Healthy CEM-CCRF cells (12 3 10 6 ) were washed in 10 mL washing buffer. Cells were resuspended in 6 flow tubes with the following treatments: (1) Just Cells. Incubated 1 hour RT, washed 2 3 with 2 mL WB.
